PHIA Koninklijke Philips N.V.

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures



May 19, 2025

  • VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real time
  • Catheter offers enhanced procedural guidance without the need for general anesthesia, supporting more efficient and patient-friendly care for structural heart disease

Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the introduction of its VeriSight Pro 3D Intracardiac Echocardiography (ICE) catheter in Europe. Building on its success in the United States, VeriSight Pro brings real-time 3D imaging directly inside the heart, helping physicians perform procedures with greater clarity — without the need for general anesthesia.



Designed for procedures such as transcatheter valve repair and left atrial appendage closure, VeriSight Pro offers high-resolution 2D and 3D visualization directly within the heart chambers. This enables confident clinical decision-making in structural heart and electrophysiology interventions, while removing the need for general anesthesia and associated risks.



“With VeriSight Pro 3D ICE, we now have the ability to see detailed cardiac anatomy from inside the heart in real time,” said Prof. Dr. Jörg Hausleiter, Ludwig-Maximilians-Universität (LMU) Munich, Germany. “This helps streamline our workflows and makes complex procedures more accessible to patients who may not tolerate more invasive imaging approaches.”



Addressing structural heart disease with less burden on patients and hospitals


Structural heart disease is a growing challenge across Europe, with increasing volumes of transcatheter valve repair and closure procedures. Today, many of these are supported by transesophageal echocardiography (TEE), which often requires general anesthesia, additional staff, and extended room time. In contrast, 3D ICE imaging provides detailed visualization from within the heart through a catheter introduced via the femoral vein, reducing the need for general anesthesia and recovery time in the Post-Anesthesia Care Unit (PACU), which can shorten hospital stays and lower costs.



VeriSight Pro is a pioneering innovation: a miniaturized ultrasound probe, approximately 3 millimeters in diameter, embedded at the tip of a thin, steerable catheter. This tiny device can be navigated through the vascular system and into the heart chambers, where it delivers high-quality 2D and 3D images in real time. Imaging the heart from within, with control over the scan angle, opens entirely new possibilities for guiding structural heart interventions. Physicians can assess anatomy, guide device placement, and confirm procedural results — all from a single access point, and without the need for more invasive imaging techniques.

As the first ICE catheter to miniaturize the same 3D imaging technology used in TEE, VeriSight Pro helps address key barriers in delivering efficient, scalable care — from patient tolerance to resource availability in interventional suites.



“VeriSight Pro reflects our ongoing commitment to delivering clinically relevant innovations that enhance precision, reduce procedure complexity, and improve the care experience,” said Stacy Beske, Business Leader of Image-Guided Therapy Devices at Philips. “Its availability in Europe is an important milestone in helping more patients benefit from image-guided, minimally invasive heart procedures, while supporting care teams with integrated solutions that adapt to the way they work.”



Part of an integrated portfolio for structural heart care


VeriSight Pro is part of Philips’ structural heart disease ecosystem, seamlessly integrating with Philips’ EPIQ ultrasound systems, which in turn integrate with the Azurion image-guided therapy platform. Combined with tools such as EchoNavigator, Philips offers an end-to-end solution for clinicians performing procedures such as tricuspid and mitral valve repair and replacement, atrial septal defect closure, and left atrial appendage occlusion.



The catheter’s unique features — including xPlane and iRotate technologies — allow physicians to visualize two imaging planes simultaneously and digitally adjust views without physically repositioning the catheter tip. These capabilities enable precise assessment and device deployment with fewer imaging steps.



Showcasing 3D ICE in action at EuroPCR 2025


Philips will highlight VeriSight Pro and its role in structural heart interventions at EuroPCR 2025 in Paris, May 20–23. Key activities include:

  • Physician-led symposium: “Advanced Imaging in Structural Heart Disease Interventions” (Tuesday, May 20), featuring case insights from U.S. and European clinicians using 3D ICE and AI-assisted imaging.
  • Hands-on training village: Real-world imaging practice with VeriSight Pro on Mentice simulators, supported by Philips experts and in collaboration with Edwards Lifesciences.
  • Immersive VR-based launch training: Invite-only program showcasing clinical protocols for left atrial appendage occlusion and TV TEER, including headset-based live procedure simulations.

These sessions will offer clinicians an in-depth look at how 3D ICE is being applied in real-world structural heart procedures — from imaging protocols to workflow integration and clinical outcomes. A complete and detailed overview of sessions can be found here: .



For further information, please contact:



Joost Maltha

Philips Global External Relations

Tel.: 6

E-Mail:



About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.



Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,200 employees with sales and services in more than 100 countries. News about Philips can be found at .

Attachment



EN
19/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips Foundation 2024 Annual Report: expanding access to quality hea...

Philips Foundation 2024 Annual Report: expanding access to quality healthcare for 46.5 million people In 2024, Philips Foundation initiated 22 new projects and 5 new impact investments expanding its impact and reach in innovative healthcare delivery to India and South AmericaCelebrating a decade of impact with strong progress towards the Foundation’s 2030 goal to improve access to healthcare for 100 million people in underserved communities a yearThe combined impact of longstanding strategic collaborations and new innovative partnerships with healthcare ventures affirm the Foundation’s appr...

 PRESS RELEASE

Philips announces exchange ratio for 2024 dividend

Philips announces exchange ratio for 2024 dividend June 5, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been g...

ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Ageas: Reinsurance partnership with TRIGLAV, taking QS on Italian motor direct insurance Belgian Telecoms: Digi introduces a new mobile subscription at €3. Kinepolis: Box office in US/Canada up 76% YoY while France visitors were down 25%. NN Group & ASR: Dutch coalition collapse not affecting Dutch Pension Reform. SBM Offshore: Farewell Aseng after 13.5 years of service. Events Calendar

Marc Hesselink ... (+3)
  • Marc Hesselink
  • CFA
  • Thymen Rundberg

Benelux Tech update/Our favourites: ASM, Barco, BESI, RELX

We refresh our Benelux Tech coverage following the 1Q25 reporting season. In this note we downgrade Just Eat Takeaway from Buy to HOLD as we believe the takeover offer is fair. Most companies reported largely in line results and, across the board we make relatively modest changes to our estimates. Our highest conviction longs in the Benelux Tech universe are ASM International, Barco, BE Semiconductor Industries and RELX. Our biggest increase in target price is for Prosus which saw strong perfor...

 PRESS RELEASE

Philips to repurchase up to 6 million shares to cover long-term incent...

Philips to repurchase up to 6 million shares to cover long-term incentive plans June 4, 2025  Amsterdam, the Netherlands –  (NYSE: PHG, AEX: PHIA) today announced that it will repurchase up to 6 million shares to cover certain of its obligations arising from its long-term incentive plans. At the current share price, the shares represent an amount of up to approximately EUR 125 million. The repurchases will be executed through one or more individual forward transactions, to be entered into in the course of the second and third quarter of 2025, in accordance with the Market Abuse Regulation...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch